Alkermes Initiates Phase 2 Vibrance-1 Trial of Narcolepsy Agent ALKS 2680
Craig Hopkinson, MD(Credit: LinkedIn)According to a recent announcement, Alkermes has initiated its randomized, double-blind, dose-range-finding, placebo-controlled phase 2 Vibranc...
Improvements in Neurological Assessments and Decreased Biological Age Seen With Alzheimer Agent Bezisterim
In a randomized, placebo-controlled trial, bezisterim (BioVie), an oral, small molecule, blood-brain permeable compound in development for Alzheimer disease (AD), demonstrated pote...
NeurologyLive® Brain Games: May 12, 2024
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topi...
Basal Ganglia Activity Associated With REM Sleep Behavior Disorder in Parkinson Disease
Jian-Guo Zhang, MD, PhD(Credit: Capital Medical University)Newly published in the Journal of Neurology, Neurosurgery and Psychiatry, findings showed that basal ganglia activities a...
CSF Anti-DAGLA Autoantibodies Identified as Potential Biomarker of Rapidly Progressive Cerebellitis
Kurt-Wolfram Sühs, MD(Credit: Hannover Medical School)In a small-scale study published in the Journal of Neurology, Neurosurgery & Psychiatry, investigators identified diacylglyce...
PrimeC Performs Well in High-Risk ALS, Patient Death Reported in DAYLIGHT Trial, Donanemab AdComm Hearing Date Announced
WATCH TIME: 4 minutesWelcome to this special edition of Neurology News Network. I’m Marco Meglio.Newly announced analyses from the phase 2b PARADIGM trial showed that treatment wi...
FDA Grants Breakthrough Therapy Designation for AOC 1001 in Myotonic Dystrophy Type 1
Sarah Boyce(Credit: Avidity)According to a recent announcement, the FDA has granted breakthrough therapy designation to AOC 1001 (Avidity Biosciences), an investigational treatment...
NeurologyLive® Friday 5 — May 10, 2024
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and...
Depression Predisposes Parkinson Disease, Associated With Worse Disease Severity
Using data from more than 430,000 participants with 14.1 years of follow-up, findings from a recently published study showed that depression is common in patients with Parkinson di...
Early Treatment Response and Safety Profile of AXS-05 in Phase 3 ACCORD Trial: Anton P. Porsteinsson, MD
WATCH TIME: 6 minutes'It's important because when patients finally seek treatment for agitation and aggression that’s been going on for quite a while and has gotten to a critical ...
